Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29536 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Minji Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency, Cheongju, South Korea. Hauptthemen laut MEDLINE: Benzamides, Immunocompromised Host. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Disease Control and Prevention Agency.
Abstract (Originalsprache)
Following the worldwide surge in mpox (monkeypox) in 2022, cases have persisted in Asia, including South Korea, and sexual contact is presumed as the predominant mode of transmission, with a discernible surge in prevalence among immunocompromised patients. Drugs such as tecovirimat can result in drug‐resistant mutations, presenting obstacles to treatment. This study aimed to ascertain the presence of tecovirimat‐related resistant mutations through genomic analysis of the monkeypox virus isolated from a reported case involving prolonged viral shedding in South Korea. Here, tecovirimat‐resistant mutations, previously identified in the B.1 clade, were observed in the B.1.3 clade, predominant in South Korea. These mutations exhibited diverse patterns across different samples from the same patient and reflected the varied distribution of viral subpopulations in different anatomical regions. The A290V and A288P mutant strains we isolated hold promise for elucidating these mechanisms, enabling a comprehensive analysis of viral pathogenesis, replication strategies, and host interactions. Our findings imply that acquired drug‐resistant mutations, may present a challenge to individual patient treatment. Moreover, they have the potential to give rise to transmitted drug‐resistant mutations, thereby imposing a burden on the public health system. Consequently, the meticulous genomic surveillance among immunocompromised patients, conducted in this research, assumes paramount importance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency, Cheongju, South Korea.
ORCID-Profile: Yoon-Seok Chung
Förderung
- Korea Disease Control and Prevention Agency
Zitieren
APA
Lee, M., Choi, C. H., Kim, J. W., Sim, G., Lee, S. E., Shin, H., Lee, J. H., Choi, M. M., Yi, H., & Chung, Y. S. (2024). Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment. Journal of Medical Virology. https://doi.org/10.1002/jmv.29536
Vancouver
Lee M, Choi CH, Kim JW, Sim G, Lee SE, Shin H, et al. Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment. Journal of Medical Virology. 2024. doi:10.1002/jmv.29536
BibTeX
@article{Lee2024,
author = {Lee, Minji and Choi, Chi-Hwan and Kim, Jin-Won and Sim, Gyuri and Lee, Sang Eun and Shin, Hwachul and Lee, Jeong Hyun and Choi, Myung-Min and Yi, Hwajung and Chung, Yoon-Seok},
title = {Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29536}
}
EUVIMED